Business information company Thomson Reuters, US, has announced a partnership agreement with Sagient Research, a leading provider of biopharmaceutical institutional research. Under the deal, Thomson Reuters will incorporate Sagient's assessments, forecasts and approval timelines on clinical-stage drugs into the upcoming Forecast Module of Thomson Pharma Partnering.
The Forecast Module, in beta testing now, is scheduled for release in the fourth quarter. It will integrate Sagient's data with comprehensive scientific and commercial analysis of the industry pipeline from Thomson Reuters, providing a combination of data to help biopharma companies and investors assess new drugs. The product will be the first on the market to put forecasting tools together with deep intelligence on the industry pipeline, enabling quicker, higher quality sales forecasts. It will provide ratings of the likelihood of drug approvals, monitor upcoming events that will affect those approvals, and provide multiple perspectives on sales forecasts, including downloadable Excel models that allow customers to tailor with their own assumptions.
Thomson Pharma Partnering provides all of the information companies need to find and form the right partnerships, including detailed information on drugs in development, their market potential, the companies developing them, and comparable partnering deals.
Search for more such Forecasting tools in K-Store
Discuss this NEWS
